{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:41:42Z","timestamp":1770820902143,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004426","name":"Dr. Werner Jackst\u00e4dt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004426","id-type":"DOI","asserted-by":"publisher"}]},{"name":"retina.net"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["PA 4282\/1-1"],"award-info":[{"award-number":["PA 4282\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die photodynamische Therapie (PDT) wurde urspr\u00fcnglich zur Behandlung der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration (nAMD) sowie der sekund\u00e4ren chorioidalen Neovaskularisation im Rahmen einer Myopie (mCNV) zugelassen. Zudem wird sie im Rahmen einer Off-label-Therapie bei Patienten mit Aderhauth\u00e4mangiom, polypoidaler chorioidaler Vaskulopathie (PCV) sowie Chorioretinopathia centralis serosa (CCS) eingesetzt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>Das Ziel dieser Arbeit war es, die Entwicklung der PDT-Behandlungszahlen in Deutschland zwischen 2006 und 2021 nachzuzeichnen und die Zusammensetzung der Indikationen f\u00fcr die Behandlung zu untersuchen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>In dieser retrospektiven Studie wurden die Qualit\u00e4tssicherungsberichte der deutschen Krankenh\u00e4user in dem Zeitraum von 2006 bis 2019 ausgewertet und die Anzahl der durchgef\u00fchrten PDT erfasst. Zudem wurde das Indikationsspektrum f\u00fcr eine PDT exemplarisch an der Klinik f\u00fcr Augenheilkunde des Universit\u00e4tsklinikums Freiburg und dem Augenzentrum am St. Franziskus Hospital in M\u00fcnster zwischen 2006 bis 2021 ermittelt. Anhand der gesch\u00e4tzten Pr\u00e4valenz der CCS und der Chronifizierungsrate wurde schlussendlich die Anzahl der theoretisch behandlungsbed\u00fcrftigen CCS-Patienten in Deutschland modelliert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die Anzahl der in Deutschland durchgef\u00fchrten PDT ist von 1072 Behandlungen im Jahr 2006 auf 202 Behandlungen im Jahr 2019 zur\u00fcckgegangen. W\u00e4hrend die PDT im Jahr 2006 in 86\u202f% der F\u00e4lle bei Patienten mit nAMD und in 7\u202f% der F\u00e4lle bei mCNV eingesetzt wurde, wurde sie in den Jahren 2016 bis 2021 vornehmlich bei Patienten mit CCS (70\u202f%) und Aderhauth\u00e4mangiomen (21\u202f%) durchgef\u00fchrt. Bei einer gesch\u00e4tzten Pr\u00e4valenz der CCS von 1:10.000 und unter der Annahme, dass 16\u202f% der F\u00e4lle eine behandlungsbed\u00fcrftige chronische CCS (cCCS) entwickeln, m\u00fcssten in Deutschland ca.\u00a01330 PDT allein f\u00fcr die neu an einer cCCS erkrankten Patienten pro Jahr durchgef\u00fchrt werden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Die in Deutschland r\u00fcckl\u00e4ufige Anzahl an durchgef\u00fchrten PDT ist v.\u00a0a. durch eine Umstellung auf die intravitreale Therapie f\u00fcr die nAMD und mCNV zu erkl\u00e4ren. Da die PDT aktuell die Therapie der Wahl f\u00fcr die cCCS darstellt, ist von einer Unterversorgung der PDT in Deutschland auszugehen. Es sind zur Gew\u00e4hrleistung einer ad\u00e4quaten Versorgung der Patienten die robuste Verf\u00fcgbarkeit von Verteporfin, eine vereinfachte Bewilligungsstruktur seitens der Krankenkassen sowie eine enge Kooperation zwischen niedergelassenen Augen\u00e4rzten und gr\u00f6\u00dferen Zentren notwendig.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-023-01825-5","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:26:39Z","timestamp":1679862399000},"page":"818-824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Photodynamische Therapie in Deutschland\u00a0\u2013 Quo vadis?","Photodynamic therapy in Germany\u2014Quo vadis?"],"prefix":"10.1007","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7671-8391","authenticated-orcid":false,"given":"L.","family":"Pauleikhoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Rothaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gro\u00df-B\u00f6lting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"B\u00f6hringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Retina.Net CCS Register Studiengruppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"1825_CR1","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/s0002-9394(02)02222-5","volume":"135","author":"IA Barbazetto","year":"2003","unstructured":"Barbazetto\u00a0IA, Lee\u00a0TC, Rollins\u00a0IS et\u00a0al (2003) Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 135:898\u2013899. https:\/\/doi.org\/10.1016\/s0002-9394(02)02222-5","journal-title":"Am J Ophthalmol"},{"key":"1825_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/s0161-6420(02)01998-x","volume":"110","author":"KJ Blinder","year":"2003","unstructured":"Blinder\u00a0KJ, Blumenkranz\u00a0MS, Bressler\u00a0NM et al (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2\u2011year results of a\u00a0randomized clinical trial\u2014VIP report no. 3. Ophthalmology 110:667\u2013673. https:\/\/doi.org\/10.1016\/s0161-6420(02)01998-x","journal-title":"Ophthalmology"},{"key":"1825_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1136\/bjo.87.12.1453","volume":"87","author":"W-M Chan","year":"2003","unstructured":"Chan\u00a0W\u2011M, Lam\u00a0DSC, Lai\u00a0TYY et al (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a\u00a0novel treatment at the primary disease level. Br J Ophthalmol 87:1453\u20131458","journal-title":"Br J Ophthalmol"},{"key":"1825_CR4","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","volume":"111","author":"W-M Chan","year":"2004","unstructured":"Chan\u00a0W\u2011M, Lam\u00a0DSC, Lai\u00a0TYY et al (2004) Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a\u00a0prospective case series. Ophthalmology 111:1576\u20131584. https:\/\/doi.org\/10.1016\/j.ophtha.2003.12.056","journal-title":"Ophthalmology"},{"key":"1825_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001443","author":"A Daruich","year":"2017","unstructured":"Daruich\u00a0A, Matet\u00a0A, Marchionno\u00a0L et\u00a0al (2017) Acute central SEROUS CHORIORETINOPATHY: factors influencing episode duration. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000001443","journal-title":"Retina"},{"key":"1825_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","volume":"125","author":"EHC van Dijk","year":"2018","unstructured":"van Dijk\u00a0EHC, Fauser\u00a0S, Breukink\u00a0MB et al (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 125:1547\u20131555. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.021","journal-title":"Ophthalmology"},{"issue":"01","key":"1825_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15623\/ijret.2014.0301002","volume":"3","author":"G Kaur","year":"2014","unstructured":"Kaur G. (2014) Usage of regular expressions in NLP. Int J Res Eng Technol IJERT. 3(01):7","journal-title":"Int J Res Eng Technol IJERT."},{"key":"1825_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","volume":"115","author":"AS Kitzmann","year":"2008","unstructured":"Kitzmann\u00a0AS, Pulido\u00a0JS, Diehl\u00a0NN et\u00a0al (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002. Ophthalmology 115:169\u2013173. https:\/\/doi.org\/10.1016\/j.ophtha.2007.02.032","journal-title":"Ophthalmology"},{"key":"1825_CR9","doi-asserted-by":"publisher","unstructured":"Berufsverband der Augen\u00e4rzte Deutschlands e.V. (BVA), Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft e.V. (RG) (2022) Stellungnahme von BVA, DOG und RG zur Chorioretinopathia centralis serosa (CCS). Klin Monatsbl Augenheilkd 239:217\u2013232. https:\/\/doi.org\/10.1055\/a-1725-3125","DOI":"10.1055\/a-1725-3125"},{"key":"1825_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2147\/CLEP.S310542","volume":"13","author":"J Luebke","year":"2021","unstructured":"Luebke\u00a0J, Boehringer\u00a0D, Anton\u00a0A et\u00a0al (2021) Trends in surgical glaucoma treatment in Germany between 2006 and 2018. Clin Epidemiol 13:581\u2013592. https:\/\/doi.org\/10.2147\/CLEP.S310542","journal-title":"Clin Epidemiol"},{"key":"1825_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-021-01376-7","author":"L Pauleikhoff","year":"2021","unstructured":"Pauleikhoff\u00a0L, Agostini\u00a0H, Lange\u00a0C (2021) Central serous chorioretinopathy. Ophthalmologe. https:\/\/doi.org\/10.1007\/s00347-021-01376-7","journal-title":"Ophthalmologe"},{"key":"1825_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ajo.2021.06.020","volume":"233","author":"TJ van Rijssen","year":"2021","unstructured":"van Rijssen\u00a0TJ, van Dijk\u00a0EHC, Tsonaka\u00a0R et al (2021) Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol 233:101\u2013110. https:\/\/doi.org\/10.1016\/j.ajo.2021.06.020","journal-title":"Am J Ophthalmol"},{"key":"1825_CR13","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen\u00a0TJ, van Dijk\u00a0EHC, Yzer\u00a0S et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.07.003","journal-title":"Prog Retin Eye Res"},{"key":"1825_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011841.pub2","author":"M Salehi","year":"2015","unstructured":"Salehi\u00a0M, Wenick\u00a0AS, Law\u00a0HA et al (2015) Interventions for central serous chorioretinopathy: a\u00a0network meta-analysis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011841.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1825_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth\u00a0U, Chong\u00a0V, Loewenstein\u00a0A et al (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144\u20131167. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702","journal-title":"Br J Ophthalmol"},{"key":"1825_CR16","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/s0161-6420(02)01454-9","volume":"109","author":"UM Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth\u00a0UM, Michels\u00a0S, Kusserow\u00a0C et al (2002) Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results. Ophthalmology 109:2284\u20132294. https:\/\/doi.org\/10.1016\/s0161-6420(02)01454-9","journal-title":"Ophthalmology"},{"key":"1825_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15148","author":"MJ Sirks","year":"2022","unstructured":"Sirks\u00a0MJ, van Dijk\u00a0EHC, Rosenberg\u00a0N et\u00a0al (2022) Clinical impact of the worldwide shortage of verteporfin (Visudyne\u00ae) on ophthalmic care. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.15148","journal-title":"Acta Ophthalmol"},{"key":"1825_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0002-9394(01)00967-9","volume":"131","author":"Verteporfin In Photodynamic Therapy Study Group","year":"2001","unstructured":"Verteporfin In Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a\u00a0randomized clinical trial including lesions with occult with no classic choroidal neovascularization\u2014verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541\u2013560. https:\/\/doi.org\/10.1016\/s0002-9394(01)00967-9","journal-title":"Am J Ophthalmol"},{"key":"1825_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/s0161-6420(01)00544-9","volume":"108","author":"Verteporfin in Photodynamic Therapy Study Group","year":"2001","unstructured":"Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1\u2011year results of a\u00a0randomized clinical trial\u2014VIP report no. 1. Ophthalmology 108:841\u2013852. https:\/\/doi.org\/10.1016\/s0161-6420(01)00544-9","journal-title":"Ophthalmology"},{"key":"1825_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/00006982-200306000-00002","volume":"23","author":"LA Yannuzzi","year":"2003","unstructured":"Yannuzzi\u00a0LA, Slakter\u00a0JS, Gross\u00a0NE et al (2003) Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a\u00a0pilot study. Retina 23:288\u2013298. https:\/\/doi.org\/10.1097\/00006982-200306000-00002","journal-title":"Retina"},{"key":"1825_CR21","doi-asserted-by":"crossref","unstructured":"(1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials\u2014TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 117:1329\u20131345","DOI":"10.1001\/archopht.117.10.1329"},{"key":"1825_CR22","unstructured":"Photodynamic therapy for vasoproliferative retinal tumors : retina. https:\/\/journals.lww.com\/retinajournal\/Fulltext\/2006\/04000\/PHOTODYNAMIC_THERAPY_FOR_VASOPROLIFERATIVE_RETINAL.4.aspx. Zugegriffen: 30. Dez. 2021"},{"key":"1825_CR23","unstructured":"R: The R Project for Statistical Computing. https:\/\/www.r-project.org\/. Zugegriffen: 30. Dez. 2021"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01825-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-023-01825-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-023-01825-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:04:39Z","timestamp":1691492679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-023-01825-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1007\/s00347-023-01825-5","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"20 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Pauleikhoff, K.\u00a0Rothaus, F.\u00a0Gro\u00df-B\u00f6lting, D.\u00a0B\u00f6hringer, J.\u00a0L\u00fcbke, H.\u00a0Agostini und C.\u00a0Lange geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}